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http://www.biomedcentral.com/1471-2334/14/91RESEARCH ARTICLE Open AccessEfficacy of isoniazid prophylactic therapy in
prevention of tuberculosis in children:
a meta–analysis
James Ayieko1,4*, Lisa Abuogi2, Brett Simchowitz3,4, Elizabeth A Bukusi1, Allan H Smith4 and Arthur Reingold4Abstract
Background: Children are highly susceptible to tuberculosis; thus, there is need for safe and effective preventive
interventions. Our objective was to evaluate the efficacy of isoniazid in prevention of tuberculosis morbidity and
mortality in children aged 15 years or younger by performing a meta-analysis of randomized controlled trials. To
our knowledge, this is the first meta-analysis evaluating efficacy of isoniazid prophylaxis in prevention of tuberculosis
in children.
Methods: A systematic search of the literature was done to identify randomized controlled trials evaluating isoniazid
prophylaxis efficacy among children. Each study was evaluated for relevance and validity for inclusion in the analysis.
Subgroup analyses were conducted based on study quality, HIV status, tuberculosis endemicity, type of prophylaxis
and age of participants.
Results: Eight studies comprising 10,320 participants were included in this analysis. Upon combining data from all
eight studies, isoniazid prophylaxis was found to be efficacious in preventing development of tuberculosis, with a
pooled RR of 0.65 (95% CI 0.47, 0.89) p = 0.004 , with confidence intervals adjusted for heterogeneity. Among the
sub-group analyses conducted, only age of the participants yielded dramatic differences in the summary estimate
of efficacy, suggesting that age might be an effect modifier of the efficacy of isoniazid among children, with no
effect realised in children initiating isoniazid at four months of age or earlier and an effect being present in older
children. Excluding studies in which isoniazid was initiated at four months of age or earlier yielded an even stronger
effect (RR = 0.41 (95% CI 0.31, 0.55) p <0.001). Data on the effect of isoniazid on all-cause mortality, excluding studies
in which isoniazid was initiated in infants, yielded an imprecise estimate of mortality benefit (RR = 0.58 (95% CI 0.31, 1.09)
p = 0.092).
Conclusion: Isoniazid prophylaxis reduces the risk of developing tuberculosis by 59% among children aged 15 years or
younger excluding children initiated during early infancy for primary prophylaxis (RR = 0.41, 95% CI 0.31, 0.55 p < 0.001) .
However, further studies are needed to assess effects on mortality and to determine prophylaxis effectiveness in very
young children and among HIV-infected children.
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Tuberculosis (TB) is a potentially lethal, infectious disease
caused by Mycobacterium tuberculosis [1]. Worldwide,
there were an estimated 8.7 million incident cases of TB in
2011 and approximately 1.4 million deaths (430,000 among
people who were HIV-infected) [2]. TB is now recognized
as being second only to HIV/AIDS as the greatest killer
worldwide caused by a single infectious agent and as the
leading cause of mortality among people living with HIV
[3], making it an important public health problem that
requires effective intervention.
Children are highly susceptible to infection with M. tu-
berculosis, and once infected, are at much higher risk of
progression to TB than adults [4]. This risk is greatest
for infants and children < 2 years of age because of the
immaturity of the immune system [5,6]. The situation is
worse for those infected with HIV due to the accom-
panying immunosuppression that HIV infection causes.
As a result, there is a need to protect this susceptible
group from developing TB using safe and effective
strategies.
Isoniazid (INH) is one of the first line medications
used in multi-drug regimens for treatment of TB; as a
single drug, it is also used to prevent M. tuberculosis
infection and progression from latent infection to TB
[7]. While many studies have demonstrated the effective-
ness of INH prophylaxis in adults [8], there have been
only a few studies in children, and these have produced
conflicting results. Our objective was to evaluate the effi-
cacy of isoniazid prophylaxis in prevention of tubercu-
losis morbidity and mortality in children ≤ 15 years of
age by performing a meta-analysis of RCTs (randomized
controlled trials). This paper attempts to estimate more
precisely the efficacy of INH prophylaxis in all children
by pooling data from existing studies. To our knowledge,
this is the first meta-analysis to explore this question, other
than a Cochrane review published in 2009 that was limited
to a single study of HIV-infected children [9].
Methods
We included only randomized controlled trials (RCTs)
involving children aged ≤ 15 years, regardless of their
HIV status, comparing INH (4–20 mg/kg) with placebo
or no prophylaxis. The studies had to have been pub-
lished in English in peer-reviewed journals. Publications
were of any date through October 2012. Studies were
restricted to RCTs to provide the strongest evidence for
the efficacy of INH.
Search methods and data collection
RCTs were identified through a search of PubMed,
Embase, Aidsonline, Google Scholar and Cochrane data-
base electronically and by reviewing the references of
identified articles (Figure 1). The following search termswere used: isoniazid, INH, prophylaxis, preventive ther-
apy, children, tuberculosis, TB, HIV as listed in titles and
abstracts, and randomized controlled trial as publication
type. The search included all English articles through
October 2012.
Two reviewers searched and evaluated trials for inclu-
sion in the analysis, and data were collated and checked
by both reviewers before inclusion. Discrepancies were
resolved by consensus.
The quality of each RCT included in this analysis was
graded by use of a validated score that included the fol-
lowing items (10): randomization of participants, double-
blind evaluation, and a description of participants who
withdrew from or dropped out of the trial. The scoring
gives one point for each item present. If randomization is
concealed and the method of double-blind evaluation is
appropriate, the study is assigned one additional point for
each of these, yielding a score of 0–5 points. Studies that
scored three or more points were considered to be high
quality studies, while those with a score below three were
considered to be low quality studies. To supplement this
score we used the Cochrane criteria to grade concealment
of treatment allocation as: adequate (A), unclear (B), inad-
equate (C), or allocation was not used (D) [10].
Statistical analysis
Most studies presented their results using risk ratios
(RRs). For those that included both adults and children,
we disaggregated the raw data and calculated RRs and the
corresponding 95% confidence intervals for the children
separately. Analysis was performed using the intention-to-
treat principle.
The summary RR estimates were calculated using both
the fixed effects inverse variance weighting method [11]
and the DerSimonian-Laird random effects method [12].
Heterogeneity among studies was assessed using the
general variance-based method [13]. If heterogeneity was
present, confidence intervals in the fixed effects model
were adjusted to account for between-study variance
using the method presented by Shore et al. [14].The
advantage of this approach is that it still weights by pre-
cision, while also taking heterogeneity into account.
Heterogeneity of INH efficacy between studies was in-
vestigated using the I2 statistic. An I2 value of >50% was
considered an indicator of substantial heterogeneity
(values of I2 equal to 25%, 50%, and 75% were deemed
to represent low, moderate, and high heterogeneity,
respectively). In addition, significant heterogeneity was
deemed to be present when the Chi2 test statistic was
greater than the degrees of freedom. To explore hetero-
geneity among studies, we performed subgroup analyses
based on the HIV status of the children, duration of ad-
ministration of INH prophylaxis (< or ≥ six months), age
of participants (arbitrary cut-off set at 5 years of age),
2063 articles identified in PUBMED, 
Embase, AIDSOnline, Cochrane database 
Google scholar
RCTs included in the meta-analysis (n=8)
1 study comparing 
different doses of INH, 
13 with INH in 
combination with other 
2004 articles not relevant 
from title
3RCTs lack disaggregated 
results, 3 cohort studies
(n=59)
(n=28)
RCTs 
(n=22)
13 Adult studies, 6 meta-
analyses, 12 reviews
Figure 1 Diagram of systematic search (Flow Diagram).
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where the study was conducted, and quality of the study.
Primary prophylaxis here refers to administration of INH
for prevention of TB infection while secondary prophy-
laxis refers to administration of INH to prevent TB
disease. Sensitivity analyses were also carried out to
assess the influence of individual studies on the summary
effect estimate.
Publication bias was assessed by plotting the logarithm
of the RR for each study by its standard error (SE) [15]
and explored using a funnel plot. Publication bias was
also assessed using the Egger [16] and Begg tests [17].
An absence of publication bias would be indicated by an
even dispersion of effect sizes around the pooled effect
estimate. All meta-analyses risk estimates, graphs and
plots were performed using STATA, version 12.1.
Results
Of 2063 articles initially identified, eight studies (com-
prising 10,320 children) were included in this analysis
(Figure 1) [18-24], two of which were presented in asingle article by Madhi et al. [19]. Madhi’s article [19] in-
cluded two independent sets of participants; those who
were HIV positive and those who were HIV negative but
had been exposed to HIV (i.e. born to a HIV- infected
mother but, themselves HIV uninfected). We considered
HIV infection as a potential effect modifier and chose to
treat these two subsets as separate studies.
Table 1 provides information about the characteristics
of the trials included in the analysis. Among the eight
studies, two included participants (n = 810) who were
HIV-infected [18,19]; one included HIV negative partici-
pants born to HIV-infected mothers (n = 806) [19], and
the other five included only HIV negative participants
(n = 8,703) irrespective of their exposure status [20-24].
Three of the eight studies included participants who
were tuberculin skin test (TST) positive only [21,22,24],
and two studies excluded participants who had BCG scars
[22,24]. Three of the trials were conducted in southern
Africa, one in India, one in France, one in Kenya, one
in the US, and one at multiple sites in Mexico, the US
and Canada. The quality of six of the trials [18-21,23] was
Table 1 Studies included in the pooled analysis
Author(Year) Sample
size(n)
Age of
participants
Dosage Location Quality
score
Risk Ratio %Weight
using FEM*
Madhi et al. (2011) [19] 547 <4 months 10–20 mg/kg South Africa and
Botswana
5A 0.98(0.7,1.39) 32.4%
Madhi et al. (2011) [19] 806 <4 months 10–20 mg/kg South Africa and
Botswana
5A 0.86(0.57,1.29) 22.8%
Zar et al. (2007) [18] 263 <51 months 10(8–12)mg/kg South Africa 5A 0.28(0.1,0.78) 3.6%
Gupta et al. (1993) [24] 167 5–15 years 15 mg/kg India 1D 0.61(0.3,1.25) 7.5%
Debre et al. (1973) [22] 2,307 5–14 years 5–15 mg/kg France 1D 0.40(0.15,1.05) 4.0%
Egsmose et al. (1965) [20] 406 0–15 years 5–10 mg/kg Kenya 5A 0.38(0.16,0.88) 5.2%
Comstock et al. (1962) [23] 3,074 2 months–15 years 4–8 mg/kg Alaska 5A 0.33(0.07,1.64) 1.5%
Mount et al. (1961) [25] 2,750 0–15 years 4–6 mg/kg USA, Canada,
Mexico
5A 0.40(0.27,0.61) 22.9%
Total 10,320 100%
*FEM-Fixed Effects Model.
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quality [22,24].
In two of the trials, INH prophylaxis was administered
for a duration of less than six months, while in the other
six it was administered for six months or longer. The
duration of follow-up among the studies varied from
5.7 months to 10 years. Six studies indicate that they
used tablets, the studies by Gupta et.al and Debre et.al
did not indicate the formulation used. Two of the eight
studies used INH for prevention of primary infection;
three studies used it for secondary prevention of TB,
and the remaining three for both primary and secondary
prevention. All studies with the exception of the study
by Comstock et al., followed up participants actively.
The studies used a combination of clinical signs and
symptoms, radiological findings and bacteriological in-
vestigations to make a diagnosis of TB. All studies, with
the exception of that by Gupta et al., give a comprehen-
sive explanation of how the diagnosis was arrived at.
The results of the meta-analysis are shown in Table 2.
Combining data from all eight studies, there was a 35%
reduction in the risk of developing TB among those who
were randomized to receive INH (RR = 0.65, 95% CI
0.47, 0.89 p = 0.004). In subgroup analyses, only the age
of participants was found to yield substantial differences
in the summary estimate of the effect of INH, suggesting
that age might be an effect modifier of the efficacy of
INH prophylaxis among children. No effect was noted
in children on whom INH was initiated at an age of
four months or earlier for primary prophylaxis of TB
(RR =0.93, 95% CI 0.71, 1.21 p = 0.29) while INH had
an effect in older children aged 5 to 15 years (RR = 0.53,
95% CI 0.30, 0.94 p = 0.014). Excluding studies focused
on INH prophylaxis in infants (Madhi et al.) yielded a
greater protective effect (RR = 0.41 (95% CI 0.31, 0.55)
p <0.001).On pooling the eight studies, marked heterogeneity in
the efficacy of INH was observed (Chi2 18.56, df = 7,
I2 = 64.3% p = 0.01) (Figure 2); upon conducting a
sensitivity analysis, we noted that by excluding the two
studies by Madhi et al. that included infants on whom INH
had been initiated at four months of age or earlier, the het-
erogeneity disappeared (I2 = 0.0%, p = 0.799), demonstrat-
ing that these two studies were the principal contributors
of the heterogeneity observed in the meta-analysis.
Only four trials (comprising 2,391 children) provided data
on all-cause mortality and their results were inconclusive
(mortality RR = 0.86, 95% CI 0.63, 1.17, p = 0.168) (Table 3),
(I2 = 12.2%, p = 0.332). Excluding studies in which INH was
initiated in infants at an age of four months or earlier
yielded an imprecise estimate of 42% reduction in mortality
(RR = 0.58 (95% CI 0.31, 1.09) p = 0.092).
Of the eight trials, all but one reported on the adverse
effects of INH prophylaxis. The most serious adverse ef-
fects reported were deaths of two children following over-
doses of INH in the study by Comstock et al. [23]. In the
same study, only 0.8% of the participants had adverse ef-
fects that necessitated discontinuation of INH. In the study
by Debre et al., 1% of the participants had adverse effects
that necessitated discontinuation of INH. The adverse ef-
fects reported by the other studies were less serious and
did not warrant complete discontinuation of INH.
With regard to assessment of publication bias, Figure 3
presents the funnel plot of all the studies included in this
meta-analysis (Egger test p = 0.050, Begg test p = 0.099.),
upon excluding the two infant studies by Madhi et al.
the asymmetry disappeared, (Egger test p = 0.598, Begg
test p = 0.26).
Discussion
This meta-analysis brings together trials done in varied
settings. The children in the various trials were of diverse
Overall  (I-squared = 62.3%, p = 0.010)
Comstock 1962
Madhi 2011
Debre 1973
Mount 1961
Zar 2007
Gupta 1993
Egsmose 1965
Study
ID
Madhi 2011
0.65 (0.53, 0.78)
0.33 (0.07, 1.60)
0.98 (0.70, 1.38)
0.40 (0.15, 1.06)
0.40 (0.27, 0.60)
0.28 (0.10, 0.78)
0.61 (0.30, 1.25)
0.38 (0.16, 0.89)
Risk
Ratio (95% CI)
0.86 (0.57, 1.29)
100.00
1.53
32.36
4.02
22.93
3.61
7.48
5.24
%
Weight
22.83
1.01 .5 1.5 2 2.5
Figure 2 Forest plot of all the eight studies included in the meta-analysis.
Table 2 Summary of pooled risk ratios and subgroup analyses of INH efficacy
Groups Number of
studies
Number of
participants
Fixed effects risk
ratio(95% CI*)
Random effects
risk ratio(95% CI)
Heterogeneity
Chi 2(p)
All studies 8 10,320 0.65(0.47,0.89)# 0.53(0.38,0.80) 18.56(0.00968)
High quality 6 7,845 0.66(0.45,0.98) 0.55(0.35,0.87) 17.55(0.00357)
Low quality 2 2,474 0.53(0.30,0.94) NA 0.47(0.49303)
HIV negative 6 9,509 0.55(0.40,0.75) 0.52(0.36,0.75) 8.57(0.1277)
HIV positive 2 810 0.86(0.41,1.81) 0.58(0.17,1.94) 5.14(0.02335)
TB endemic 5 2,189 0.78(0.55,1.11) 0.67(0.45,0.99) 8.93(0.06281)
TB non endemic 3 8,130 0.40(0.27,0.57) NA 0.05(0.9736)
Primary TB prophylaxis 2 1,353 0.93(0.71,1.21) NA 0.23(0.63119)
Secondary TB prophylaxis 3 5,224 0.44(0.31,0.61) NA 1.05(0.59104)
Excluding studies INH was initiated at age ≤4 months 6 8,966 0.41(0.31,0.55) NA 1.84(0.87086)
High quality excluding studies INH was initiated at
age ≤4 months
4 6,492 0.38(0.27.0.53) NA 0.43(0.93385)
INH initiated at age ≤4 months 2 1,353 0.93(0.71,1.21) NA 0.23(0.29)
Age <5 years 3 1,616 0.86(0.57,1.30) 0.77(0.48,1.23) 5.14(0.07644)
Age 5–15 years 2 2,474 0.53(0.30,0.94) NA 0.47(0.49303)
INH for ≥6 months 6 7,845 0.66(0.45,0.98) 0.55(0.35,0.87) 17.55(0.00357)
INH for <6 months 2 2,474 0.53(0.30,0.94) NA 0.47(0.49303)
*Adjusted for heterogeneity when appropriate.
#1 minus the risk ratio gives the protective effect, e.g. for the first row, 0.65 corresponds to 35% protection.
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Table 3 Effects of Isoniazid prophylaxis on all cause mortality
Study HIV status of
participants
Participant ages Risk ratio(95% CI) p value
Madhi et al. (2011) [19] Positive <4 months(median 96 days,
range 91–120 days)
1.00(0.68,1.48) 0.986
Madhi et al. (2011) [19] Negative <4 months(median 96 days,
range 91–120 days)
0.90(0.49,1.65) 0.733
Zar et al. (2007) [18] Positive <51 months (median 24.7 months,
IQR 9.4–51.6 months)
0.46(0.22,0.95) 0.015
Egsmose [20] Negative 0–15 years 0.94(0.33,2.66) 0.91
All four studies combined 0.86(0.63,1.17) 0.168
Excluding studies that INH was initiated
at age ≤4 months
0.58(0.31, 1.09) 0.092
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INH was found to provide substantial protection against
TB among children aged ≤15 years (RR = 0.65, 95% CI
0.47, 0.89 p = 0.004), however, there was marked het-
erogeneity in the efficacy of INH (Chi 2 18.56, df = 7,
I2 = 62.3% p = 0.01). We conducted a sensitivity analysis
to explore the observed heterogeneity. Most of the het-
erogeneity was noted to be due to the two studies by
Madhi et al.(also referred to as the infant studies in this
article) [19], primarily due to two reasons. First, the re-
sults of the two studies by Madhi et al. were notably dif-
ferent from the results of the other studies, in that these
two studies yielded point estimates much closer to the
null compared to the results of the other studies, with
confidence intervals that included the null, while the rest
of the studies had point estimates and confidence inter-
vals that showed that INH conferred a protective effect.
Second, both the random effects and the fixed effects0
.
2
.
4
.
6
.
8
-2 -1
lo
Funnel plot with pseudo
Figure 3 Funnel plot of all eight studies included in this meta-analysimodels gave these two studies more weight because of
their relatively large size. One plausible explanation for the
null results in the Madhi studies may be due to overdiag-
nosis of TB given that only few of the cases were con-
firmed microbiologically and many cases only met minimal
clinical criteria [19]. After excluding the two studies by
Madhi et al., the heterogeneity disappeared (I2 = 0.0%,
p = 0.799) and our analysis yielded an even greater effect
estimate (RR = 0.41 (95% CI 0.31, 0.55) p <0.001).
One possible explanation for the discrepancy between
findings from Madhi et al. and from the remaining stud-
ies has to do with the age of the participants at initiation
of INH. Whereas subjects in the Madhi et al. trials were
infants (median age 96 days, range 91–120 days) at the
time of INH initiation, the remaining studies involved
mostly older children, suggesting that age may modify
the effect of INH prophylaxis on the development of TB.
This hypothesis is supported by subgroup analyses based0 1
g RR
 95% confidence limits
s.
Ayieko et al. BMC Infectious Diseases 2014, 14:91 Page 7 of 10
http://www.biomedcentral.com/1471-2334/14/91on five studies that investigated differential INH effi-
cacy by age. INH was found to be more effective among
children aged 5–15 years (RR = 0.53, 95% CI 0.30, 0.94
p = 0.014) than among children less than five years of
age (RR = 0.85, 95% CI 0.54, 1.35 p = 0.25) (Table 2). As
mentioned previously, INH did not appear to confer
any protective effect against TB in the infant studies
(RR = 0.93, 95% CI 0.71, 1.21 p = 0.29).The lack of effect
observed may be due to the relative immaturity of the in-
nate immune system among younger as opposed to older
children considering existing evidence suggesting that
the dosage delivered in these studies was sufficient to
achieved therapeutic levels [26]. We also acknowledge
that age might be a confounding factor for prior TB ex-
posure, given that in the Madhi et al. study, INH was
used for primary prophylaxis compared to the other
studies in which it was used for either secondary prophy-
laxis or both primary and secondary prophylaxis. INH is
known to be effective for the preventive treatment of la-
tent TB which would be more prevalent among older
children but it might not be as effective in preventing TB
infection. We therefore cannot fully rule out the possibil-
ity that age may be a surrogate marker for TB infection
thus explaining the higher efficacy seen in older children
consistent with the results of the primary versus second-
ary prophylaxis subgroup analysis. While age may, in fact,
be an effect modifier of the efficacy of INH, additional al-
ternative explanations proposed by Madhi et al. for the
null results in their studies include INH resistance, poor
compliance, and the specificity of the study end points
[19]. Other differences in the studies by Madhi et al.
compared to the rest were that the population had no
known history of TB exposure and the participant ages
were more uniform compared to the other studies.
Minimal differences in the efficacy of INH prophylaxis
were seen in the subgroup analyses based on duration of
administration of INH and study quality. Six trials ad-
ministered INH for a duration of six months or longer
and showed a 34% reduction in the risk of developing
TB among those randomized to receive INH, RR = 0.66
(95% CI 0.45, 0.98) p = 0.02; the rest of the trials admin-
istered INH for less than six months and still demon-
strated a protective effect against TB, RR = 0.53 (95% CI
0.30, 0.94) p = 0.014. These results suggest that adminis-
tration of INH for less than six months may be as effect-
ive as longer courses of prophylaxis among non-HIV
infected children. This finding, which is consistent with
that of other studies demonstrating only a small advan-
tage of a 12-month over a 6-month course of INH pre-
ventive therapy [27], may have important public health
implications. This would be useful if applied in high TB
endemic areas where the duration and intensity of ex-
posure might be a critical factor affecting effectiveness of
INH prophylaxis. While current guidelines for isoniazidpreventive therapy recommend six months of prophylaxis
[18], an equally effective but shorter course could result in
improved adherence to therapy in children without HIV
[28]. While the studies in this meta-analysis that adminis-
tered a shorter course of prophylaxis were of generally low
quality (Table 1) and should therefore be interpreted with
caution, these findings justify further research into the op-
timal duration of INH preventive therapy in children,
which remains uncertain [27].
Subgroup analyses based on HIV infection status
found a strong protective effect of INH against TB
among HIV-negative children (RR = 0.55, 95% CI 0.40,
0.75 p = 0.001), but no evidence of an effect among HIV-
positive children (RR = 0.86, 95% CI 0.41, 1.81 p = 0.187).
However, it is worth noting that the analysis of HIV-
infected children was limited by the inclusion of only
two studies; one in which INH was used for primary
prophylaxis in HIV-exposed infants (Madhi et al.) and
the other for secondary prophylaxis in older HIV-
infected children (Zar et al.). We note, however that the
Zar et al. study found INH to be highly effective and is
further discussed below. As mentioned above, age may,
itself, modify INH efficacy, complicating interpretation of
these results. Therefore, we are unable to make a conclu-
sive statement concerning INH efficacy among HIV-
infected children and urge further research into this
question. To our knowledge, the two studies we included
in this subgroup analysis are currently the only studies
on the efficacy of INH in prevention of TB that have been
conducted in HIV-infected children.
The results also suggest that the efficacy of INH was
greater in TB non-endemic regions (RR = 0.40, 95% CI
0.27, 0.57 p < 0.001) compared to TB endemic regions
(RR = 0.78, 95% CI 0.55, 1.11 p = 0.08). One plausible
explanation as to why isoniazid may have been less effi-
cacious in endemic regions is reinfection of the children
with a different strain of Mycobacterium tuberculosis.
However, it is important to note that the results of this
subgroup analysis may be misleading because the studies
in TB endemic regions contained a large proportion of
very young children compared to studies in the TB non-
endemic regions, and the studies that contained this cat-
egory of participants (Madhi et al.) yielded null results;
this finding, combined with the fact that the studies by
Madhi et al. received more weight in both the fixed ef-
fects and the random effects models, may explain the
null result in this subgroup analysis. Upon excluding
these two studies, we obtained a summary estimate of
RR 0.44(0.27, 0.72) p < 0.001, suggesting that INH con-
fers a protective effect in TB endemic areas as well.
Four of the eight studies included in this meta-analysis
reported results on all-cause mortality. Combining the
results of these studies (comprising 2,391 children) showed
little evidence of an effect of INH on all-cause mortality
Ayieko et al. BMC Infectious Diseases 2014, 14:91 Page 8 of 10
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findings of studies conducted on adults [29]. This estimate
however may be misleading , because two of the four stud-
ies included were the infant studies described above, where
no protective effect against TB or mortality benefit had
been demonstrated; these two studies received 77.8% of
the weight in this subgroup analysis. We thus excluded
these two studies to get a more reliable estimate (RR = 0.58
(95% CI 0.31, 1.09) p = 0.092); this estimate, though impre-
cise, may suggest a mortality benefit of INH prophylaxis.
We are limited in our ability to draw firm conclusions on
mortality benefits of INH prophylaxis due to the limited
data available, and thus recommend further studies.
A legitimate concern with expanded use of INH
prophylaxis among children is the potential for serious
adverse events resulting from therapy. This meta-
analysis, however, suggests that INH is relatively safe in
children. The most serious adverse events reported in the
studies included were the deaths of two children following
overdoses of INH in the study by Comstock et al. [23]. In
the same study, however, only 0.8% of the participants ex-
perienced adverse events that necessitated discontinuation
of the medication. The adverse events reported in the
other studies were generally mild and did not warrant dis-
continuation of INH. The study by Zar et al. reported that
the safety and tolerability of INH prophylaxis in children
were excellent, even among the HIV-infected subgroup re-
ceiving highly active antiretroviral therapy. Widespread
use of INH over several years has shown that a dosage of
5 mg/kg of body weight is unlikely to cause serious toxic
effects [23], a conclusion substantiated by this meta-
analysis and the results of other INH prophylaxis trials
[25,30-32]. Another concern is INH resistance; previous
reviews have not found a statistically significant elevated
risk of isoniazid-resistant TB among individuals previously
treated with isoniazid preventive therapy [33].
The study by Zar et al. demonstrated a marked pro-
tective effect in terms of prevention of TB (RR 0.28 (95%
CI 0.1, 0.78) p = 0.005) and TB mortality (RR 0.46 (95%
CI 0.22, 0.95) p = 0.015) among HIV-infected children
and is therefore worth commenting on [18]. The study
by Zar et al. was a landmark study that was conducted
on HIV- infected children in a TB endemic region and
demonstrated marked benefits of INH in terms of redu-
cing morbidity as well as mortality and was instrumental
in informing policy on INH prophylaxis among HIV-
infected children [34]. We note that most of the differ-
ences in mortality and incidence of TB were observed
within two months after randomization, presenting the
possibility that some of the children selected to partici-
pate in the study already had subclinical TB and the
INH was actually treating (as monotherapy) rather than
preventing TB. This scenario, if true, may have led to
an overestimation of the efficacy of INH as preventivetherapy. However, it is worth noting that if the afore-
mentioned concern is true, the findings by Zar et. al
present valuable evidence demonstrating that INH is
useful in reducing TB and mortality in HIV-infected
children with advanced disease (WHO stage 3 or 4), re-
gardless of whether a diagnosis of TB is made or not.
Diagnosis of TB in this category of children presents a
challenge, especially in resource limited settings [34].
The risk of bias in this meta-analysis arises mostly
from inclusion of two studies that were of generally low
quality. The study by Debre et al. was not conducted in
a blinded fashion, while the study by Gupta et al. did not
give details of how the randomized controlled trial was
conducted; the authors acknowledged irregularities and
defaults in drug intake in the latter study which may
have influenced their results [22,24]. Concerning all of
the studies, generally, diagnosis of TB is very difficult in
children [34], particularly in infants and this may have
led to failure to make a diagnosis, misdiagnosis or over
diagnosis of the outcome, leading to a biased estimate of
the efficacy of INH preventive therapy. This scenario is
highly likely due to the diverse diagnostic criteria used
in the different studies which is a major weakness in this
analysis. Misdiagnosis is equally likely in the treatment
and control groups so the effect was likely to be non-
differential and therefore bias estimates towards the null.
Publication bias has the potential to bias the results of
a meta-analysis [9]. We used a funnel plot to look for
evidence of publication bias [35]. While there was some
suggestion of asymmetry in the funnel plot, we are not
convinced that publication bias is a serious threat to our
findings. However, it is important to note that other fac-
tors, apart from publication bias, can cause asymmetry
in a funnel plot and affect the outcome of the Egger and
Begg tests; in addition, the validity and interpretation of
the Egger and Begg tests have been debated [36]. It
should also to be noted that the sensitivity of both the
Egger and Begg tests is low when the analysis contains
fewer than ten studies, as was the case with our meta-
analysis [37]. To establish whether publication bias was
a concern, we estimated the pooled RR from the loga-
rithm of the RR corresponding to the largest studies,
which was approximately −0.4; we exponentiated this
value, yielding an estimate of RR = 0.67, close to the esti-
mate of our pooled summary measure (RR 0.65) showing
that in this case, publication bias may not be influential
in altering the overall summary estimate. In addition, be-
cause the studies by Madhi et al. were different from the
other studies because of the ages of the participants at
INH initiation and were responsible for the asymmetry
on the funnel plot, we excluded them and re-did a fun-
nel plot; after exclusion of these two studies there was
no asymmetry (Egger test p = 0.598, Begg test p = 0.26),
providing no evidence of publication bias.
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the fact that only eight studies were deemed suitable for
inclusion, compromising the statistical power of the sub-
group analyses. Diverse TB diagnostic criteria were used
in the different studies which is a major weakness in this
analysis due to lack of standardization across studies.
Attempts have been made to standardize TB case defin-
ition in children for research purposes to prevent this
scenario in the future [38]. In addition, the studies were
of a mixed nature with some evaluating efficacy of INH
in primary TB prevention while others evaluating sec-
ondary TB prophylaxis yet others evaluating efficacy of
preventing both primary and secondary TB, this limits
comparability across the studies. Another limitation was
that we restricted our search to English language articles
and thus may have missed studies published in other lan-
guages. Furthermore, we included only RCTs in this meta-
analysis, which poses the challenge of generalizability
because trial participants are different from the general
population, owing to the fact that trials often have strict eli-
gibility criteria and those who agree to participate may be
very different from the general population.
Conclusion
The results of our analysis suggest that INH prophylaxis
reduces the risk of TB by 59% among children ≤ 15 years
of age, excluding a subset of young children on whom
INH was initiated at four months of age or earlier
for primary prophylaxis (RR = 0.41, 95% CI 0.31, 0.55
p < 0.001). INH confers a protective effect against TB
among HIV negative children; however, we had insuffi-
cient data to make a definitive conclusion on efficacy of
INH in preventing TB among HIV-infected children. In
contrast to the WHO recommendation to give all HIV-
infected children over 12 months of age isoniazid pre-
ventive therapy, our results show no effect of isoniazid
preventive therapy among this group (though from lim-
ited data) and justifies more investigation. The results
further suggest that INH is not effective among the youn-
gest children and that there is little evidence of a mortal-
ity benefit in children of any age. Based on our results,
we recommend the administration of INH to children at
risk, especially those with smear positive contacts, be-
cause, as the evidence indicates, INH will reduce their
risk of developing TB and thus help lower TB disease
burden and TB-related years lost to disability (YLD).
Due to the fact that there are limited data on the efficacy
of INH in children ≤ five years of age, in HIV-infected
children, and on overall mortality, we recommend that
further studies be carried out to answer conclusively the
question of whether INH is effective among very young
children and children who are HIV-infected, as well as to
determine the optimum duration of INH preventive ther-
apy and to assess the mortality benefit among children.Abbreviations
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